Scientists reveal liver protein that could revolutionize metabolic disease treatments

Scientists have uncovered a key molecular mechanism in liver cells that could transform treatments for metabolic liver diseases. The discovery, led by researchers including Gao, Yang, and Duan, focuses on a protein called ERRα, which plays a crucial role in regulating both glucose production and genetic stability in the liver. This breakthrough offers new hope for tackling conditions like Metabolic Associated Steatotic Liver Disease (MASLD) and its more severe form, Metabolic Associated Steatohepatitis (MASH). The study explored how ERRα, a member of the nuclear receptor family, controls liver function through two major pathways. First, it regulates genes responsible for gluconeogenesis—the process by which the liver produces glucose. Second, it influences epigenetic changes, such as modifications to histones and DNA methylation, which affect how genes are expressed without altering the genetic code itself.

Experiments used genetically modified mice and cultured liver cells to mimic human disease conditions. When ERRα was removed from liver cells, the progression of MASLD and MASH sped up significantly. Conversely, activating ERRα with drugs reduced key markers of these diseases, suggesting its protective role. The research also revealed that ERRα helps maintain healthy DNA methylation patterns in the liver, preventing genetic damage. Additionally, it boosts the activity of enzymes that add acetyl groups to histones, making it easier for gluconeogenic genes to be transcribed. These findings highlight how metabolic factors like fasting or a high-fat diet can influence ERRα activity, implying that lifestyle changes could enhance future treatments targeting this protein. By linking metabolic signals with epigenetic control, ERRα acts as a central regulator in liver health. This dual function positions it as a promising target for therapies aimed at stopping or even reversing liver disease progression.

The identification of ERRα’s role in balancing glucose metabolism and epigenetic regulation marks a significant advance in liver disease research. This work not only deepens the understanding of MASLD and MASH but also paves the way for developing new drugs that could slow or reverse these conditions. Further studies will likely explore how dietary and pharmacological interventions can optimise ERRα activity for patient benefit.